United Nations High-Level Meeting on TB Policy Note. At the first United Nations High-Level Meeting (HLM) on TB back in 2018, UN member states pledged “to mobilize sufficient and sustainable financing, with the aim of increasing overall global investments to…
As international dignitaries and political leaders gather in New York City this week for the United Nations High-Level Meeting (HLM) on TB, a sobering new analysis from Treatment Action Group (TAG) shows that governments failed to meet previous commitments to fund TB research.
Following the White House’s recent proposal for a National Hepatitis C Elimination Plan as part of its Fiscal Year 2024 budget request to Congress, and the fact that key populations for HIV are also at high risk of HCV, Treatment Action Group is organizing a webinar that will highlight best practices and challenges for HCV elimination with a specific focus on high-burden populations.
In 2017 Treatment Action Group and partners introduced the “fair share” funding targets for TB research.
Research into curing HIV infection is ever-changing as new discoveries are made and scientists report additional rare — but informative — cases of individuals likely cured of HIV.
On Thursday, April 13, Treatment Action Group (TAG) presented this webinar about important developments in TB vaccine research.
Webinar on March 22 that will provide an update on new research into cases in which the HIV reservoir generates detectable viral load that cannot be suppressed by antiretroviral therapy.
Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI).
In 2014, TAG began tracking HIV cure-related trials and observational studies and making the information available as a listing on our website. The primary sources are online study registries, particularly the US-based clinicaltrials.gov.
For the first time in history, funding for tuberculosis (TB) research and development (R&D) hit a billion dollars worldwide in 2021.